Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

20.52
+0.45002.24%
Post-market: 20.520.00000.00%16:39 EDT
Volume:605.75K
Turnover:12.45M
Market Cap:585.11M
PE:33.10
High:21.01
Open:19.86
Low:19.76
Close:20.07
Loading ...

Company Profile

Company Name:
Castle Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
761
Office Location:
505 S. Friendswood Drive,Suite 401,Friendswood,Texas,United States
Zip Code:
77546
Fax:
- -
Introduction:
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Directors

Name
Position
Daniel M. Bradbury
Chairman of the Board of Director
Derek J. Maetzold
President, Chief Executive Officer and Director
Bonnie H. Anderson
Director
David Kabakoff
Director
G. Bradley Cole
Director
Joseph C. Cook III
Director
Mara G. Aspinall
Director

Shareholders

Name
Position
Derek J. Maetzold
President, Chief Executive Officer and Director
Bernhard E. Spiess
Chief Operating Officer
Frank Stokes
Chief Financial Officer
Federico A. Monzon
Chief Medical Officer